3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
CNS
1
Breast
1
Conditions
Glioblastoma
18
Glioma
9
Astrocytoma
6
Neuroblastoma
5
Gliosarcoma
5
Brain Neoplasms
5
Sarcoma, Ewing
4
Neoplasms
4
Recurrence
3
Oligodendroglioma
3
Sarcoma
2
Rhabdomyosarcoma
2
Medulloblastoma
2
Hepatoblastoma
2
Central Nervous System Neoplasms
2
Wilms Tumor
1
Spinal Cord Neoplasms
1
Rhabdoid Tumor
1
Refractory Solid Tumors
1
Prostatic Neoplasms
1
Pheochromocytoma
1
Paraganglioma
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Osteosarcoma
1
Neuroectodermal Tumors, Primitive, Peripheral
1
Neoplasm Metastasis
1
Marijuana Abuse
1
Lymphoma, Follicular
1
Ganglioneuroblastoma
1
Interventions
Magnetic Resonance Spectroscopy
28
enzalutamide
23
Specimen Handling
20
apalutamide
17
Androgen Antagonists
14
Radiosurgery
13
Radiotherapy
12
Prednisone
12
Docetaxel
12
Abiraterone Acetate
12
abiraterone
10
Biopsy
10
Radiation
8
niraparib
6
luprolide acetate gel depot
6
darolutamide
6
Pluvicto
6
Leuprolide
6
2-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid
6
relugolix
5
gallium 68 PSMA-11
5
cabazitaxel
5
acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide
5
Nivolumab
5
Gonadotropin-Releasing Hormone
5
bicalutamide
4
Triptorelin Pamoate
4
Surveys and Questionnaires
4
Radiotherapy, Intensity-Modulated
4
Glutamate Carboxypeptidase II
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Prostatic Neoplasms
×
Temozolomide
×
30 days
×
Clear all
NCT05417594
2026-05-05
CERTIS1
AstraZeneca
Phase 1/2
Recruiting
695 enrolled